Diagnosis and Treatment of Non-Muscle Invasive Bladder Cancer: AUA/SUO Guideline
详细信息    查看全文
文摘
Although associated with an overall favorable survival rate, the heterogeneity of non-muscle invasive bladder cancer (NMIBC) affects patients’ rates of recurrence and progression. Risk stratification should influence evaluation, treatment and surveillance. This guideline attempts to provide a clinical framework for the management of NMIBC.

sSec_2">Materials and Methods

spara0015">A systematic review utilized research from the Agency for Healthcare Research and Quality (AHRQ) and additional supplementation by the authors and consultant methodologists. Evidence-based statements were based on body of evidence strength Grade A, B, or C and were designated as Strong, Moderate, and Conditional Recommendations with additional statements presented in the form of Clinical Principles or Expert Opinions.<span id="bbib1"><sup>1sup>span>

sSec_3">Results

spara0020">A risk-stratified approach categorizes patients into broad groups of low-, intermediate-, and high-risk. Importantly, the evaluation and treatment algorithm takes into account tumor characteristics and uniquely considers a patient&rsquo;s response to therapy. The 38 statements vary in level of evidence, but none include Grade A evidence, and many were Grade C.

sSec_4">Conclusion

spara0025">The intensity and scope of care for NMIBC should focus on patient, disease, and treatment response characteristics. This guideline attempts to improve a clinician&rsquo;s ability to evaluate and treat each patient, but higher quality evidence in future trials will be essential to improve level of care for these patients.

© 2004-2018 中国地质图书馆版权所有 京ICP备05064691号 京公网安备11010802017129号

地址:北京市海淀区学院路29号 邮编:100083

电话:办公室:(+86 10)66554848;文献借阅、咨询服务、科技查新:66554700